Genmab jumps as ovarian cancer data bolster confidence ahead of Phase III readout

Genmab A/S

05/10/2026 08:37

** Genmab GMAB.CO rises 4% after presenting updated Phase II data for its ovarian cancer drug Rina-S, showing a clinically meaningful response rate
** Jefferies says the results de-risk the programme ahead of a key Phase III readout in Q4
** The brokerage reiterates its "buy" rating and raises its price target to DKK 2,900 ($434) from DKK 2,800, increasing its probability of success for Rina-S to 60% from 50%
** Broker says durability of response compares favourably with ovarian cancer drug Elahere and could beat expectations if confirmed in late-stage trials
** Jefferies cites encouraging survival trends, evidence of benefit across patient groups and a reassuring safety profile
** Today's gains added 5.4 billion Danish crowns ($808.42 million)to company's market cap


($1 = 6.6797 Danish crowns)


 (Reporting by Agnieszka Gosciak-Rabalska)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))